Physician profile
Taylor Michael Smith
NPI 1194213025
$9,324.47
in general payments reported to CMS, 2019-2025
21 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,837 · 2022: $1,885 · 2023: $2,287 · 2024: $2,141 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,602.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,424.84 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,099.85 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,007.67 | 2021-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $706.98 | 2021-2022 | |
| Corium, LLC | $547.95 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $540.11 | 2021-2024 | Jornay Pm |
| Lundbeck LLC | $532.94 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $484.74 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $448.46 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $447.67 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $415.43 | 2021-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $375.56 | 2021-2024 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $255.84 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $238.18 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $205.27 | 2023-2024 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $176.15 | 2021-2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $115.99 | 2022-2023 | Quviviq |
| Noven Therapeutics, LLC | $112.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $96.58 | 2022-2023 | Belsomra |
| Neos Therapeutics, Lp | $78.02 | 2022-2025 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.